What did PIONEER-1 do with participants who could not tolerate a step?

My records go back to the first dose with dates, so I can reconstruct the timeline exactly.

The figures are clear enough; the question is what they mean and what they do not.

I can supply the numbers if the specifics change the answer.

What would I need in addition before this supported a decision?

PIONEER-1 would have written it into the protocol, and the wording is the part that matters. Escalation protocols in this class generally permit a delay at the current level, sometimes a single step down with a later re-attempt, and count a participant as remaining in the arm throughout. That is analytically important: an intention-to-treat analysis keeps them at their randomised assignment regardless of the dose they were actually taking, so the "top dose" arm contains people who never reached the top dose. Find the protocol amendment history as well as the paper, because tolerability rules are among the things most often revised mid-programme, and dose-escalation decisions are made under supervision — nothing here is medical advice.

Escalating while symptomatic resets the tolerance process and is the mechanism behind most miserable titrations.

The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.

Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.

Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.

Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.

Hold rather than escalate while symptoms are active. Always.

Answering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.

Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.

Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.

A schedule described here is a published schedule for a licensed product and is not a recommendation.

The top of the schedule is not the target. The working dose is.

Answer first: the titration schedule exists to let tolerance to the gastrointestinal effects develop between steps, and every step in it is a tolerability decision rather than an efficacy one.

The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.

Concretely, titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Four half-lives between steps, minimum. Work it out for your agent.

edited 10 Apr 2026 by plate_count_9k — fixed an arithmetic slip in the third paragraph

The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.

The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.

Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.

Slower costs time and nothing else. The ceiling is the same.

This is the single most consequential controllable variable in the whole experience, and people routinely rush it.

For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.

Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.

Stepping back is a normal adjustment, not a failure.